RenovoRx Announces Proposed Public Offering

Announces Proposed Public Offering

VIEW, Calif.-(BUSINESS WIRE)- RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life

sciences company developing novel targeted oncology therapies and commercializing RenovoCath , a novel, FDA-cleared delivery

platform, today announced that it has commenced an underwritten public offering of shares of its common stock or pre-funded warrants

to purchase shares of common stock. All of the securities to be sold in the proposed offering will be offered by RenovoRx. The proposed

offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed,

or the actual size or terms of the offering.

intends to use the net proceeds received from the offering for working capital and general corporate purposes, including continued progression

of its Phase III TIGeR-PaC study and the continued development and execution of commercial sales and marketing activities for RenovoCath

as a standalone device.

Partners Group, a division of American Capital Partners, is acting as the sole bookrunner for the offering.

offering is being made by RenovoRx pursuant to a shelf registration statement on Form S-3 (File No. 333-268302) previously filed with

the Securities and Exchange Commission (the "SEC") on November 10, 2022, which became effective on November 21, 2022. The

offering is being made only by means of a preliminary prospectus supplement and the accompanying base prospectus that form a part of

the registration statement. A preliminary prospectus supplement and the accompany base prospectus relating to the offering will be filed

with the SEC and will be available on the SEC's website at www.sec.gov. Copies of the preliminary prospectus supplement

and the accompanying base prospectus, and when available, copies of the final prospectus supplement and the accompanying base prospectus

relating to the offering, may be obtained by contacting Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World

Trade Center, 29th Floor, New York, NY 10007, by phone at (929) 833-1246 or by email at prospectus@titanpartnersgrp.com.

press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities

in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under

the securities laws of such state or jurisdiction.

is a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath , a novel, U.S.

Food and Drug Administration (FDA)-cleared local drug-delivery platform, targeting high unmet medical needs. RenovoRx's patented

Trans-Arterial Micro-Perfusion (TAMP ) therapy platform is designed to ensure precise therapeutic delivery across the arterial

wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous

therapy. RenovoRx's novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy,

and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic

and therapeutic agents.

Phase III lead product candidate is a novel oncology drug-device combination product. It is being investigated under a U.S. investigational

new drug application that is regulated by the FDA's 21 CFR 312 pathway. The investigational drug-device combination candidate utilizes

RenovoCath, the Company's FDA-cleared drug-delivery device, indicated for temporary vessel occlusion in applications including

arteriography, preoperative occlusion, and chemotherapeutic drug infusion. The intra-arterial infusion of chemotherapy, gemcitabine,

utilizing the RenovoCath catheter is currently being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the

Center for Drug Evaluation and Research (the drug division of FDA).

intra-arterial infusion of gemcitabine by the RenovoCath catheter is currently under investigation and has not been approved for commercial

sale. RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides 7 years

of market exclusivity upon NDA approval by the FDA.

is also engaged in implementing commercialization strategies utilizing its TAMP technology and FDA-cleared RenovoCath delivery system

as a stand-alone device. In December 2024, RenovoRx announced the receipt of its first commercial purchase orders for RenovoCath devices.

Additionally, over ten medical institutions have initiated the process for RenovoCath purchase orders. To meet and satisfy the anticipated

demand, RenovoRx will continue to actively explore further revenue-generating activity either on its own or in tandem with a medical

device commercial partner.

more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and X.

Note Regarding Forward-Looking Statements

press release and statements of the Company's management made in connection therewith and at the investor conference described

herein contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities

Exchange Act of 1934, including but not limited to statements regarding the timing, size and completion of the proposed public offering

as well as the expected use of proceeds related thereto. Statements that are not purely historical are forward-looking statements. The

forward-looking statements contained herein are based upon the Company's current expectations and beliefs regarding future events,

many of which, by their nature, are inherently uncertain, outside of the Company's control and involve assumptions that may never

materialize or may prove to be incorrect. These may include estimates, projections and statements relating to the Company's research

and development plans, intellectual property development, clinical trials, the Company's therapy platform, business plans, financing

plans, objectives and expected operating results, which are based on current expectations and assumptions that are subject to known and

unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these

forward-looking statements. These statements may be identified using words such as "may," "expects," "plans,"

"aims," "anticipates," "believes," "forecasts," "estimates," "intends,"

and "potential," or the negative of these terms or other comparable terminology regarding RenovoRx's expectations strategy,

plans or intentions, although not all forward-looking statements contain these words. These forward-looking statements are subject to

a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated

by such statements, including, among other things: RenovoRx's ability to complete the offering on the proposed terms, or at all,

changes in market conditions, and RenovoRx's expectations related to the use of proceeds from the proposed offering. Information

regarding the foregoing and additional risks may be found in the section entitled "Risk Factors" in documents that the Company

files from time to time with the SEC.

statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking

statements to reflect subsequent events or circumstances, except as required by law.

Strategic Communications

Valter Pinto or Jack Perkins